NCT06941272 2026-03-13
MK-9999-01C
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
Clinical Trials
3 trialsNCT03260491 2026-03-05
U3-1402 in Metastatic or Unresectable Non-Small Cell Lung Cancer
Daiichi Sankyo
Phase 1 Active not recruiting
NCT02980341 2024-10-30
Phase I/II Study of U3-1402 in Subjects With Human Epidermal Growth Factor Receptor 3 (HER3) Positive Metastatic Breast Cancer
Daiichi Sankyo
Phase 1/2 Completed